Pharmacology and the Nursing Process, 4th ed. Lilley/Harrington
Download
Report
Transcript Pharmacology and the Nursing Process, 4th ed. Lilley/Harrington
Chapter 46
Antineoplastic Drugs Part 2: Cell Cycle
– Nonspecific Drugs and
Miscellaneous Drugs
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Cancer Drugs:
Antineoplastic Medications
Cell cycle–nonspecific (CCNS) antineoplastic
drugs
Alkylating drugs
Cytotoxic antibiotics
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
2
Alkylating Drugs
Classic alkylators (nitrogen mustards)
Nitrosoureas
Miscellaneous alkylators
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
3
Alkylating Drugs: Mechanism of
Action
Work by preventing cancer cells from
reproducing
Alter the chemical structure of the cells’
deoxyribonucleic acid (DNA)
Bifunctional or polyfunctional
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
4
Organization of DNA and Site of
Action of Alkylating Drugs
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
5
Alkylating Drugs: Indications
Used in combination with other drugs to treat
various types of cancer, such as:
Recurrent ovarian cancer
Brain tumors
Lymphomas
Leukemias
Breast cancer
Bladder cancer
Others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
6
Alkylating Drugs: Adverse Effects
Dose-limiting adverse effects
Alopecia
Nephrotoxicity, peripheral neuropathy, ototoxicity
Nausea and vomiting, myelosuppression
Hydration can prevent nephrotoxicity
Extravasation causes tissue damage and
necrosis
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
7
Alkylating Drugs: Examples
cisplatin (Platinol)
cyclophosphamide (Cytoxan)
mechlorethamine (Mustine, nitrogen mustard)
carmustine (BiCNU)
Others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
8
Cytotoxic Antibiotics
Natural substances produced by the mold
Streptomyces
Synthetic substances also used
Used to treat cancer; too toxic to treat infections
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
9
Cytotoxic Antibiotics (cont’d)
Anthracycline antibiotics
daunorubicin, doxorubicin, epirubicin, idarubicin,
valrubicin
Other cytotoxic antibiotics
bleomycin, dactinomycin, mitomycin, mitoxantrone,
plicamycin
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
10
Cytotoxic Antibiotics: Mechanism of
Action
CCNS drugs are active in all phases of the cell
cycle
Act by intercalation, resulting in blockade of DNA
synthesis
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
11
Cytotoxic Antibiotics: Indications
Used in combination chemotherapy regimens
Used to treat a variety of solid tumors and some
hematologic malignancies
Leukemia, ovarian, breast, bone, others
Squamous cell carcinomas
AIDS-related Kaposi’s sarcoma (when intolerant to
other treatments)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
12
Cytotoxic Antibiotics:
Adverse Effects
All can produce bone marrow suppression,
except bleomycin
Hair loss, nausea and vomiting,
myelosuppression
Heart failure (daunorubicin)
Acute left ventricular failure (doxorubicin)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
13
Cytotoxic Antibiotics:
Adverse Effects (cont’d)
Pulmonary fibrosis and pneumonitis (bleomycin)
Liver, kidney, and cardiovascular toxicities
Many others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
14
Cytotoxic Antibiotics:
Adverse Effects (cont’d)
Cardiomyopathy is associated with large
amounts of doxorubicin
Routine monitoring of cardiac ejection fraction with
multiple-gated acquisition (MUGA) scans
Cumulative dose limitations
Cytoprotective drugs such as dexrazoxane can
decrease the incidence of this devastating toxicity
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
15
Classroom Response Question
Which cytotoxic antibiotic does the nurse identify
as most likely to cause pulmonary fibrosis?
A. plicamycin
B. mitoxantrone
C. mitomycin
D. bleomycin
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
16
Miscellaneous Antineoplastics
bevacizumab (Avastin)
Angiogenesis inhibitor
Blocks blood supply to the growing tumor
Used to treat metastatic colon cancer, rectal cancer in
combination with 5-fluorouracil, non–small cell lung
cancer, and malignant glioblastoma
Many adverse effects, including nephrotoxicity
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
17
Classroom Response Question
Bevacizumab (Avastin) is an angiogenesis inhibitor. Which
statement correctly describes the mechanism of action of
an angiogenesis inhibitor?
A. It inhibits the formation of blood cells.
B. It inhibits the creation of new blood vessels in the tumor
mass.
C. It interferes with the synthesis of DNA in the cancer
tumor.
D. It causes cell death by inhibiting enzymes.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
18
Miscellaneous Antineoplastics
(cont’d)
hydroxyurea (Hydrea, Droxia)
Action similar to antimetabolites
Used to treat squamous cell carcinoma and some
leukemias
Many adverse effects (e.g., edema, drowsiness,
headache, rash, hyperuricemia, nausea, vomiting,
dysuria, myelosuppression, nephrotoxicity, pulmonary
fibrosis)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
19
Miscellaneous Antineoplastics
(cont’d)
imatinib (Gleevec)
Used to treat chronic myeloid leukemia (CML)
Targeted therapy, but it is NOT a monoclonal antibody
Works by inhibiting an enzyme that is active in the
CML process
Use with other hepatic-metabolized drugs may cause
severe interactions
Many adverse effects and drug interactions
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
20
Miscellaneous Antineoplastics
(cont’d)
mitotane (Lysodren)
Adrenal cytotoxic drug
Used specifically for inoperable adrenal corticoid
carcinoma
Oral form only
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
21
Hormonal Drugs
Used to treat a variety of neoplasms in men and
women
Hormonal therapy used to
Oppose effects of hormones
Block the body’s sex hormone receptors
Used most commonly as adjuvant and palliative
therapy
But may be a drug of first choice for some cancers
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
22
Hormonal Drugs for FemaleSpecific Neoplasms
Aromatase inhibitors
Selective estrogen receptor modulators
megestrol (Megace), medroxyprogesterone
Androgens
tamoxifen, toremifene
Progestins
anastrozole, aminoglutethimide
fluoxymesterone, testolactone
Estrogen receptor antagonist
fulvestrant
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
23
Hormonal Drugs for Male-Specific
Neoplasms
Antiandrogens
Gonadotropin-releasing hormone antagonists
bicalutamide, flutamide, nilutamide
leuprolide, goserelin
Antineoplastic hormone
estramustine
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
24
Radiopharmaceuticals
and Antineoplastics
Porfimer sodium
Used to treat esophageal and bronchial tumors in
combination with laser light therapy
Radiopharmaceuticals
Used to treat a variety of cancers, or symptoms
caused by cancers
Administered by nuclear medicine specialists
• samarium SM 153 lexidronam
• sodium iodide I 131
• sodium phosphate P 32
• Others
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
25
Extravasation
Leaking of an antineoplastic drug into
surrounding tissues during IV administration
Can result in permanent damage to nerves,
tendons, muscles; loss of limbs
Skin grafting or amputation may be necessary
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
26
Extravasation (cont’d)
Prevention is essential
Continuous monitoring of the IV site is essential
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
27
Extravasation (cont’d)
If suspected, stop the infusion immediately and
contact the prescriber, but leave the intravenous
catheter in place
Aspirate any residual drug and/or blood from the
catheter
Consult guidelines or the pharmacist regarding
antidotes, application of hot or cold packs and/or
sterile occlusive dressings, and elevation and rest of
the affected limb
Thoroughly document the extravasation incident
Consult facility protocol and guidelines
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
28
Classroom Response Question
When handling and administering vesicant drugs the
nurse will:
A. double-flush the patient’s bodily secretions in the
commode.
B. use sterile towels to clean up after chemotherapy
spills.
C. mix chemotherapeutic drugs in the patient’s room.
D. teach the patient how to administer parenteral
chemotherapeutic drugs.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
29
Nursing Implications
Assess baseline blood counts before
administering antineoplastic drugs
Follow specific administration guidelines for
each antineoplastic drug
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
30
Nursing Implications (cont’d)
Alkylating drugs
Monitor for expected effects of bone marrow
suppression
Expect nausea, vomiting, diarrhea, stomatitis
Hydration is important to prevent nephrotoxicity
Report ringing/roaring in the ears—possible
ototoxicity
Report tingling, numbness, or pain in extremities—
peripheral neuropathies may occur
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
31
Nursing Implications (cont’d)
Cytotoxic antibiotics
Expect bone marrow suppression, nausea, vomiting,
diarrhea, stomatitis
Monitor pulmonary status, since pulmonary fibrosis
may occur
Monitor for nephrotoxicity, liver toxicity
Monitor cardiovascular status
Daunorubicin may turn the urine a reddish color
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
32
Nursing Implications (cont’d)
In general:
Monitor closely for anaphylactic reactions
Keep epinephrine, antihistamines, and
antiinflammatory drugs on hand
Monitor closely for complications associated with
bone marrow suppression
• Anemia, thrombocytopenia, neutropenia
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
33
Nursing Implications (cont’d)
Cytoprotective drugs may be used to reduce
toxicities
IV amifostine to reduce renal toxicity associated with
cisplatin
IV or PO allopurinol to reduce hyperuricemia
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
34
Nursing Implications (cont’d)
Monitor for oncologic emergencies
Infections
Pulmonary toxicity
Allergic reactions
Stomatitis with severe ulcerations
Bleeding
Metabolic aberrations
Bowel irritability with diarrhea
Renal, liver, cardiac toxicity
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
35